Supriya Lifescience Ltd., a cGMP-compliant API manufacturer with a presence in more than 120 countries, has released its unaudited consolidated financial statements for the first quarter ended June 30, 2026.

Revenue for Q1 FY27 grew 30.8% year-over-year to Rs. 189.75 crore, up from Rs. 145.07 crore in Q1 FY26. 

However, profitability contracted during the quarter: EBITDA stood at Rs. 47.46 crore, down from Rs. 51.70 crore a year earlier, with EBITDA margin narrowing to 25.0% from 35.6%. 

Profit After Tax (PAT) came in at Rs. 24.04 crore, compared to Rs. 34.79 crore in Q1 FY26, with PAT margin falling to 12.7% from 24.0%. Quarterly EPS stood at Rs. 2.99, down from Rs. 4.32 in the year-ago quarter.

The Anaesthetic segment remained the company's largest therapeutic contributor in Q1 FY27, accounting for 48% of revenue, down from 53% in Q1 FY26. Vitamins grew their share to 17% of revenue, up from 11% a year earlier.

Asia emerged as the company's largest market during the quarter, contributing 39% of revenue compared to 32% in Q1 FY26, while Europe accounted for 35%. 

LATAM contributed 20% of revenue, with North America and other markets contributing 3% each. Export revenue stood at 81% of the quarter's total, reflecting the company's continued focus on global markets and geographic diversification.

Dr. Satish Wagh, Executive Chairman and Whole-Time Director of Supriya Lifescience Ltd., said Q1 FY27 reflects continued momentum in the company's core business, supported by strong revenue growth and a diversified presence across global markets. 

He noted that the company's focus remains on expanding its product portfolio, strengthening manufacturing and R&D capabilities, and scaling new products across key therapeutic segments.